{"organizations": [], "uuid": "54b4023daf8b0732acba3dd1284d6d490553d6d6", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-esperion-says-phase-3-long-term-sa/brief-esperion-says-phase-3-long-term-safety-study-of-bempedoic-acid-met-primary-endpoint-idUSASC09YYM", "country": "US", "domain_rank": 408, "title": "BRIEF-Esperion Says Phase 3 Long-Term Safety Study Of Bempedoic Acid Met Primary Endpoint", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-02T14:53:00.000+03:00", "replies_count": 0, "uuid": "54b4023daf8b0732acba3dd1284d6d490553d6d6"}, "author": "", "url": "https://www.reuters.com/article/brief-esperion-says-phase-3-long-term-sa/brief-esperion-says-phase-3-long-term-safety-study-of-bempedoic-acid-met-primary-endpoint-idUSASC09YYM", "ord_in_thread": 0, "title": "BRIEF-Esperion Says Phase 3 Long-Term Safety Study Of Bempedoic Acid Met Primary Endpoint", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "long-term safety study of bempedoic acid met primary endpoint", "sentiment": "negative"}, {"name": "esperion therapeutics inc", "sentiment": "none"}, {"name": "esperion", "sentiment": "none"}, {"name": "bempedoic acid met primary endpoint reuters", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 2, 2018 / 11:53 AM / Updated 7 minutes ago BRIEF-Esperion Says Phase 3 Long-Term Safety Study Of Bempedoic Acid Met Primary Endpoint Reuters Staff\nMay 2 (Reuters) - Esperion Therapeutics Inc:\n* ESPERION ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PIVOTAL PHASE 3 LONG-TERM SAFETY STUDY OF BEMPEDOIC ACID\n* ESPERION THERAPEUTICS INC - STUDY MET PRIMARY ENDPOINT OF SAFETY AND TOLERABILITY IN LARGEST AND LONGEST DURATION STUDY\n* ESPERION - PATIENTS TREATED WITH BEMPEDOIC ACID ALSO ACHIEVED A SIGNIFICANT REDUCTION OF 22 PERCENT IN HIGH-SENSITIVITY C-REACTIVE PROTEIN Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-05-02T14:53:00.000+03:00", "crawled": "2018-05-02T15:10:36.005+03:00", "highlightTitle": ""}